Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia

Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia

The prevalence of Parkinson’s disease (PD) increases with age. Up to 50% of PD show cognitive decline in terms of a mild cognitive impairment already in early stages that predict the development of dementia, which can occur in up to 80% of PD patients over the long term, called Parkinson’s disease d...

Full description

Bibliographic Details
Main Authors: Jesse, Sarah, Lehnert, Stefan, Jahn, Olaf, Parnetti, Lucilla, Soininen, Hilkka, Herukka, Sanna-Kaisa, Steinacker, Petra, Tawfik, Saskia, Tumani, Hayrettin, von Arnim, Christine A. F., Neumann, Manuela, Kretzschmar, Hans A., Kulaksiz, Hasan, Lenter, Martin, Wiltfang, Jens, Ferger, Boris, Hengerer, Bastian, Otto, Markus
Format: Online
Language:English
Published: Public Library of Science 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493604/
id pubmed-3493604
recordtype oai_dc
spelling pubmed-34936042012-11-09 Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia Jesse, Sarah Lehnert, Stefan Jahn, Olaf Parnetti, Lucilla Soininen, Hilkka Herukka, Sanna-Kaisa Steinacker, Petra Tawfik, Saskia Tumani, Hayrettin von Arnim, Christine A. F. Neumann, Manuela Kretzschmar, Hans A. Kulaksiz, Hasan Lenter, Martin Wiltfang, Jens Ferger, Boris Hengerer, Bastian Otto, Markus Research Article The prevalence of Parkinson’s disease (PD) increases with age. Up to 50% of PD show cognitive decline in terms of a mild cognitive impairment already in early stages that predict the development of dementia, which can occur in up to 80% of PD patients over the long term, called Parkinson’s disease dementia (PDD). So far, diagnosis of PD/PDD is made according to clinical and neuropsychological examinations while laboratory data is only used for exclusion of other diseases. The aim of this study was the identification of possible biomarkers in cerebrospinal fluid (CSF) of PD, PDD and controls (CON) which predict the development of dementia in PD. For this, a proteomic approach optimized for CSF was performed using 18 clinically well characterized patients in a first step with subsequent validation using 84 patients. Here, we detected differentially sialylated isoforms of Serpin A1 as marker for differentiation of PD versus PDD in CSF. Performing 2D-immunoblots, all PDD patients could be identified correctly (sensitivity 100%). Ten out of 24 PD patients showed Serpin A1 isoforms in a similar pattern like PDD, indicating a specificity of 58% for the test-procedure. In control samples, no additional isoform was detected. On the basis of these results, we conclude that differentially sialylated products of Serpin A1 are an interesting biomarker to indicate the development of a dementia during the course of PD. Public Library of Science 2012-11-08 /pmc/articles/PMC3493604/ /pubmed/23144969 http://dx.doi.org/10.1371/journal.pone.0048783 Text en © 2012 Jesse et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Jesse, Sarah
Lehnert, Stefan
Jahn, Olaf
Parnetti, Lucilla
Soininen, Hilkka
Herukka, Sanna-Kaisa
Steinacker, Petra
Tawfik, Saskia
Tumani, Hayrettin
von Arnim, Christine A. F.
Neumann, Manuela
Kretzschmar, Hans A.
Kulaksiz, Hasan
Lenter, Martin
Wiltfang, Jens
Ferger, Boris
Hengerer, Bastian
Otto, Markus
spellingShingle Jesse, Sarah
Lehnert, Stefan
Jahn, Olaf
Parnetti, Lucilla
Soininen, Hilkka
Herukka, Sanna-Kaisa
Steinacker, Petra
Tawfik, Saskia
Tumani, Hayrettin
von Arnim, Christine A. F.
Neumann, Manuela
Kretzschmar, Hans A.
Kulaksiz, Hasan
Lenter, Martin
Wiltfang, Jens
Ferger, Boris
Hengerer, Bastian
Otto, Markus
Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
author_facet Jesse, Sarah
Lehnert, Stefan
Jahn, Olaf
Parnetti, Lucilla
Soininen, Hilkka
Herukka, Sanna-Kaisa
Steinacker, Petra
Tawfik, Saskia
Tumani, Hayrettin
von Arnim, Christine A. F.
Neumann, Manuela
Kretzschmar, Hans A.
Kulaksiz, Hasan
Lenter, Martin
Wiltfang, Jens
Ferger, Boris
Hengerer, Bastian
Otto, Markus
author_sort Jesse, Sarah
title Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
title_short Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
title_full Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
title_fullStr Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
title_full_unstemmed Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson’s Disease Dementia
title_sort differential sialylation of serpin a1 in the early diagnosis of parkinson’s disease dementia
description The prevalence of Parkinson’s disease (PD) increases with age. Up to 50% of PD show cognitive decline in terms of a mild cognitive impairment already in early stages that predict the development of dementia, which can occur in up to 80% of PD patients over the long term, called Parkinson’s disease dementia (PDD). So far, diagnosis of PD/PDD is made according to clinical and neuropsychological examinations while laboratory data is only used for exclusion of other diseases. The aim of this study was the identification of possible biomarkers in cerebrospinal fluid (CSF) of PD, PDD and controls (CON) which predict the development of dementia in PD. For this, a proteomic approach optimized for CSF was performed using 18 clinically well characterized patients in a first step with subsequent validation using 84 patients. Here, we detected differentially sialylated isoforms of Serpin A1 as marker for differentiation of PD versus PDD in CSF. Performing 2D-immunoblots, all PDD patients could be identified correctly (sensitivity 100%). Ten out of 24 PD patients showed Serpin A1 isoforms in a similar pattern like PDD, indicating a specificity of 58% for the test-procedure. In control samples, no additional isoform was detected. On the basis of these results, we conclude that differentially sialylated products of Serpin A1 are an interesting biomarker to indicate the development of a dementia during the course of PD.
publisher Public Library of Science
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493604/
_version_ 1611922889662005248

Similar Items